Nurix Therapeutics Expands its Board of Directors with the Addition of Two Industry Leaders - GlobeNewswire -BoardProspects

Nurix Therapeutics Expands its Board of Directors with the Addition of Two Industry Leaders

GlobeNewswire Sep 30 2021 BoardMoves

SAN FRANCISCO, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the appointments of Judith A. Reinsdorf and Paul M. Silva to its board of directors, effective October 1, 2021...
Read Full Article

Bookmark or Share this article

Login to comment.
Related Articles
- NACD Directorship 100 Forum Focused on Reinvigorating America also published in GlobeNewswire
- Target CEO Gregg Steinhafel Resigns In Data Breach Fallout also categorized in BoardMoves
- Rand Logistics Announces Organizational and Corporate Governance Changes also published in GlobeNewswire
- Pfizer Spinoff Zoetis Takes Pershing Square's Doyle Onto Board also categorized in BoardMoves
- Amazon's Board Diversity Push Could Destroy Traditional Retail also categorized in BoardMoves
- Airbnb Adds Outgoing American Express CEO Kenneth Chenault To Board of Directors also categorized in BoardMoves
- Cloud Foundry Board Elects EMC CTO As Chair also categorized in BoardMoves
- PepsiCo Puts Trian Business Advisor On Board also categorized in BoardMoves
- Honest Company Diversifies Its Leadership With A Second Female Board Member also categorized in BoardMoves
- Nokia Board Has Discussed Pursuit of Alcatel also mentions acquisition

Search:
Categories
1. BoardProspects Features:
  Board Recruitment Publication, BoardBlogs, BoardKnowledge, BoardMoves, BoardNews, BoardProspects Announcements, BoardProspects CEO, CEO Blog, Competitor Corner, In the News, Member Report, Partner Publications, Question of The Week, Sponsored Content
Quotes
1. I am delighted to welcome Judy and Paul to the Nurix board as we enter this important stage in the company's development and execute on our plan to advance multiple programs into clinical trials by the end of 2021.
Topics Mentioned
Authors
- Nurix Therapeutics, Inc.